The bioavailability of oral CBD is around 10%, whereas the sublingual bioavailability is at least ≥80%.17–19 Therefore, the sublingual administration of CBD in our patients could be the main explanation for this unusual finding although we cannot exclude that it is related to the intrinsic features of epilepsy in our series or to other factors. This evidence concerns the gene OPN1MW and epilepsy.